In this issue, we introduce our new series of Feature articles, celebrating the history of prosthetic heart valve innovation. Other highlights include:
Last year, cardiac surgery lost a true pioneer – Dr Albert Starr. In this issue, we reflect on his legacy and, in particular, his special partnership with Miles ‘Lowell’ Edwards that resulted in the first successful artificial heart valve to be implanted in humans.
Many breakthroughs in cardiac surgery have followed, including the development of RESILIA tissue valves. Now with over 13 years of clinical experience, RESILIA tissue has taken performance and durability to new heights, transforming the tissue valve landscape. In this issue, we share the latest data supporting the performance of RESILIA tissue, including 5-year real-world data for the INSPIRIS RESILIA valve, demonstrating that more than 65 years on, we are still committed to world-leading innovation.
Discover more on RESILIA tissue through the current and past issues below.
This healthcare professional focused booklet explores the latest clinical studies and publications involving the INSPIRIS RESILIA valve and RESILIA tissue through the review of 24 publications and abstracts.
Each reference has been summarized visually over 1 or 2 slides, for you to save time.
*Clinical data on valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up to 10-years in progress.
†RESILIA tissue tested against tissue from commercially-available bovine pericardial valves from Edwards in a juvenile sheep model. Flameng, et al. J Thorac Cardiovasc Surg 2015;149:340–5
Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).
An educational website focused on TAVI is underway
Thank you. We will keep you updated when new content is available.